Treatment Related Cancer Clinical Trial
Official title:
Therapeutic CARE of the Bronchial Cancer Not in Small Cell: Security of the Dispensation of Medicine by the Implementation of a Card of Coordination of Care Relative to the Medicinal Treatments Got Out of it From Hospitalization
NCT number | NCT03293966 |
Other study ID # | PRIMACIE |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2016 |
Est. completion date | December 31, 2017 |
Verified date | May 2018 |
Source | Groupe Hospitalier Paris Saint Joseph |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The continuity of the medicinal care between the city and the hospital stays a major
organizational stake and of safety of patients' therapeutic care.This takeover is more
complex when it concerns pathology needed lots of hospitalization and included the
intervention of multiple healthcare practionners. This is clearly the case of cancer
coverage.
The optimization of the therapeutic suppor in town is based on pharmaceutical advice
strengthening but also on the pharmaceutical analysis to check the entire treatments'
prescription and eventual medicinal interactions which ensue from it.That's why it's
important to have a medicinal conciliation that takes into account all the medecine taken or
have to be taken by the patient.
A specific support was developped by nurses , doctors and pharmacist ; it's a care
coordination card that can be put easely in a pocket by the patient.
The aim of the study is that this card can be also used as a communication tools by sharing
the prescription done at the release of hospital by using an IT link (flea datamatrix) for
the patients Via the use of an IT link (flea datamatrix) for the patients whose pathology is
complex in term of extra hospital coverage.
Status | Completed |
Enrollment | 47 |
Est. completion date | December 31, 2017 |
Est. primary completion date | February 28, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - all patient admitted in onco-thoracic service - Handled by an anticancer agent - Having frequented the same city pharmacy for at least 3 months Exclusion Criteria: - hospitalization above 21 days - refusing participation - palliative care - misunderstanding of french language - frequenting several pharmacy |
Country | Name | City | State |
---|---|---|---|
France | Groupe Hospitalier Paris Saint Joseph | Paris | Ile-de-France |
Lead Sponsor | Collaborator |
---|---|
Groupe Hospitalier Paris Saint Joseph |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite criteria including all the dysfunctions noticed at the release of the hospital prescription intended to be dispensed in town. | 7days+/- 2 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05217069 -
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
|
Phase 2 | |
Active, not recruiting |
NCT05185388 -
Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017
|
||
Withdrawn |
NCT04253249 -
Pancreatic Cyst Ablation With a Monopolar Radiofrequency Ablation Probe
|
||
Recruiting |
NCT03377829 -
A Multicenter Trial of PLA vs. Surgery for Treating PTMC
|
N/A | |
Not yet recruiting |
NCT04034173 -
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
|
Phase 2 |